A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes
Edouard L. Fu, Julianna Mastrorilli, Katsiaryna Bykov, Deborah J. Wexler, Alexander Cervone, Kueiyu Joshua Lin, Elisabetta Patorno, Julie M. Paik
Topics & Concepts
MedicineHyperkalemiaHazard ratioKidney diseaseInternal medicinePopulationType 2 diabetesCohortConfidence intervalDiabetes mellitusEndocrinologyEnvironmental healthPotassium and Related DisordersDiabetes Treatment and ManagementBipolar Disorder and Treatment